The online version of this article (doi:10.1186/1752-1947-8-223) contains supplementary material, which is available to authorized users.
The authors declare that they have no conflict of interests.
EAC conceived the idea, compiled the data and drafted the manuscript. RP and JP contributed patient data and the photographs and co-authored the final version of the manuscript. All authors read and approved the final manuscript.
Localized involutional lipoatrophy of subcutaneous adipose tissue may develop due to subcutaneous injection of pharmaceutical preparations. The pathogenesis of this adverse drug reaction is unknown. The progression of localized involutional lipoatrophy ceases and occasionally it resolves after withdrawing the inducing agent. In case of localized involutional lipoatrophy due to subcutaneous insulin therapy, low-dose systemic corticosteroids may be curative despite ongoing insulin administration.
We report a recurrence of insulin-induced localized involutional lipoatrophy at the abdominal wall in a 57-year-old Caucasian woman with type-1 diabetes on continuous subcutaneous insulin infusion. The first episode of insulin-induced localized involutional lipoatrophy two years previously had been cured by oral prednisone. The recurrence was treated immediately with 10mg prednisone once daily for five months, and was cured thereafter. The insulin analog preparation (Humalog™) and the insulin pump equipment (Accu-Chek Spirit™) applied were the same during both episodes. Both episodes were preceded by a temporary disturbance of the immune balance (the first episode by vaccination, the second episode through shingles).
This case confirms that insulin-induced localized involutional lipoatrophy in type-1 diabetes can occur again, and can be cured by systemic corticosteroids. We suggest that temporary disturbance of the immune balance may trigger this transitory idiosyncratic reaction in a susceptible individual.
Lopez X, Castells M, Ricker A, Velazquez EF, Mun E, Goldfine AB: Human insulin analog-induced lipoatrophy. Diabetes Care. 2008, 31: 443-444. CrossRef
Cabrera-Freitag P, Escalada J, Goikoetxea MJ, Laguna S, Sanz ML, Gastaminza G: A severe case of lipoatrophy due to human insulin and insulin analogs in a patient with diabetes: is an immunological mechanism involved?. J Investig Allergol Clin Immunol. 2011, 21: 417-419. PubMed
Aviles-Izquierdo JA, Longo-Imedio MI, Hernanz-Hermosa JM, Lazaro-Ochaita P: Bilateral localized lipoatrophy secondary to a single intramuscular corticosteroid injection. Dermatol Online J. 2006, 12: 17- PubMed
Petruschke T, Hauner H: Tumor necrosis factor alpha prevents the differention of human adipocyte precursor cells and causes delipidation of newly developed fat cells. J Clin Endocrinol Metab. 1993, 76: 742-747. PubMed
Salgin B, Meissner T, Beyer P, Haberland H, Borkenstein M, Fussenegger J, Brand U, Hauffa BP, Hungele A, Holl RW: Lipoatrophy is associated with an increased risk of Hashimoto’s thyroiditis and coeliac disease in female patients with type 1 diabetes. Horm Res Paediatr. 2013, 79: 368-372. CrossRefPubMed
Chakraborty PP, Bhattacharjee R: Injection site lipoatrophy: a rare complication of recombinant human insulin. J Assoc Physicians India. 2010, 58: 630- PubMed
- Insulin-induced localized lipoatrophy preceded by shingles (herpes zoster): a case report
Ernst A Chantelau
- BioMed Central